ARCH Venture Partners Discloses 11.9% Stake in Seaport Therapeutics Post-IPO, Including $19.8M IPO Purchase

summarizeSummary

ARCH Venture Partners, a prominent venture capital firm, has disclosed an 11.9% beneficial ownership stake in Seaport Therapeutics following its recent IPO, including a $19.8 million purchase of common stock at the IPO price of $18.00 per share.

check_boxKey Events

• Major Investor Stake Established

  ARCH Venture Fund XII, L.P. and affiliated entities now beneficially own 6,294,951 shares, representing 11.9% of Seaport Therapeutics' common stock.

• Significant IPO Participation

  This includes a purchase of 1,100,000 shares at $18.00 per share from the IPO underwriters on May 1, 2026, totaling $19.8 million. This purchase price is above the current market price of $16.00.

• Long-Term Commitment Indicated

  ARCH Venture Fund XII, L.P. has entered into a 180-day lock-up agreement, restricting sales of common stock post-IPO, signaling a long-term investment horizon.

• Consolidated Investment History

  The filing details prior investments in preferred stock in April and October 2024, which converted to common stock upon the IPO, providing a comprehensive view of ARCH's investment timeline.

auto_awesomeAnalysis

This Schedule 13D filing provides crucial insight into the institutional backing of Seaport Therapeutics following its recent initial public offering. The disclosure of ARCH Venture Partners' 11.9% stake, a significant position for a newly public company, signals strong confidence from a major venture capital firm. Their participation in the IPO at $18.00 per share, which is above the current market price of $16.00, further reinforces this positive sentiment. The lock-up agreement for 180 days demonstrates a commitment to long-term investment rather than short-term trading. This filing consolidates the full picture of ARCH's investment, including their pre-IPO preferred stock holdings and their recent IPO purchase, offering a comprehensive view of a key investor's position.